Last reviewed · How we verify
TNF blocker
TNF blockers inhibit tumor necrosis factor (TNF), a key inflammatory cytokine, to reduce inflammation and immune-mediated tissue damage.
TNF blockers inhibit tumor necrosis factor (TNF), a key inflammatory cytokine, to reduce inflammation and immune-mediated tissue damage. Used for Rheumatoid arthritis, Crohn's disease, Ulcerative colitis.
At a glance
| Generic name | TNF blocker |
|---|---|
| Sponsor | Centre Hospitalier Universitaire de Saint Etienne |
| Drug class | TNF inhibitor |
| Target | TNF (tumor necrosis factor) |
| Modality | Small molecule |
| Therapeutic area | Immunology |
| Phase | FDA-approved |
Mechanism of action
TNF is a pro-inflammatory cytokine central to inflammatory and autoimmune diseases. TNF blockers work by binding to and neutralizing TNF or blocking its receptors (TNFR1/TNFR2), thereby suppressing the inflammatory cascade. This reduces immune activation, decreases recruitment of inflammatory cells, and alleviates symptoms in conditions driven by excessive TNF signaling.
Approved indications
- Rheumatoid arthritis
- Crohn's disease
- Ulcerative colitis
- Ankylosing spondylitis
- Psoriasis
- Psoriatic arthritis
Common side effects
- Increased infection risk (including tuberculosis)
- Injection site reactions
- Upper respiratory tract infections
- Headache
- Demyelinating disease (rare)
Key clinical trials
- Phase II Interventional Study Evaluating Efficacy and Safety of Secukinumab in Active Severe Takayasu Patients (PHASE2)
- Biologic Treatment Withdrawal in Takayasu Arteritis Patients in Sustained Remission (NA)
- Trial of Sequential Medications AfteR TNFi Failure in Juvenile Idiopathic Arthritis (PHASE3)
- Association of Erectile Dysfunction With Neuropathic Pain, Disease Activity, and Functional Status in Male Patients With Axial Spondyloarthritis: A Cross-Sectional Observational Study
- Lumbar Spinal Fibrosis and TNF Alpha Inhibition (PHASE3)
- TNF-α Treatment of Blast-Induced Tinnitus (PHASE2)
- Real-world Study on Secukinumab Effectiveness in Biologic-naïve Ankylosing Spondylitis (AS) Patients in Korea.
- A Comparison Study of Persistence of UPadacitinib vs. TNF-inhibitoRs In a German Real-world SettING
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |